Structure Therapeutics (GPCR) Capital Expenditures (2022 - 2026)

Structure Therapeutics' Capital Expenditures history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 19.39% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $3.8 million, a 37.08% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 28.59% from the prior year.
• Capital Expenditures slipped to $1.2 million in Q1 2026 per GPCR's latest filing, from $2.1 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.8 million in Q4 2024 and bottomed at -$444000.0 in Q2 2025.
• The 5-year median for Capital Expenditures is $72000.0 (2022), against an average of $586176.5.
• Across the five-year window, Capital Expenditures tumbled 1000.0% in 2023 and soared 49400.0% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at -$24000.0 in 2022, then tumbled by 1000.0% to -$264000.0 in 2023, then surged by 1534.47% to $3.8 million in 2024, then sank by 43.99% to $2.1 million in 2025, then slumped by 44.27% to $1.2 million in 2026.
• Per Business Quant, the three latest GPCR Capital Expenditures figures stand at $1.2 million (Q1 2026), $2.1 million (Q4 2025), and $947000.0 (Q3 2025).